Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Yousif Matloub, MD, Lia Gore, MD, Mignon L. Loh, MD, Chin-Hon Pui, MD, Michael J. Hanley, PharmD, PhD, Vickie Lu, PhD, E. Jane Leonard, MSc, Muriel Granier, Andrea Biondi, MD, Lewis B. Silverman, MD

Blood (2020) 136 (Supplement 1): 47.

https://doi.org/10.1182/blood-2020-134724

Published: 2020

Journal Articles

Incidence and Therapeutic Implications of Germline TP53 Mutations in Hypodiploid Childhood Acute Lymphoblastic Leukemia: A Retrospective Analysis of the Italian Cohort

Laura Rachele Bettini, Claudia Saitta, Barbara Buldini, Geertruij Te Kronnie, Stefano Rebellato, Daniela Silvestri, Elena Barisone, Andrea Pession, Marco Rabusin, Concetta Micalizzi, Franco Locatelli, MD PhD, Carmelo Rizzari, Maria Grazia Valsecchi, PhD, Andrea Biondi, MD, Grazia Fazio, Giovanni Cazzaniga, PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-142729

Published: 2020

Journal Articles

Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141236

Published: 2020

Journal Articles

Single-Cell Profiling of Signal Transduction Pathways in Pediatric T-Cell Acute Lymphoblastic Leukemia By Mass Cytometry:Dissecting JAK/STAT and PI3K/Akt/mTOR Active Signalling

Daniela Kužílková, PhD, Tomas Kalina, MD PhD, Cristina Bugarin, Dr., Katerina Rejlová, Dr., Daniel Thurner, Dr., Pavel Semerák, Dr., Jan Stuchly, MSc, Andrea Biondi, MD PhD, Giuseppe Gaipa, PhD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-141973

Published: 2020

Journal Articles

Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A -Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-134303

Published: 2020

Journal Articles

Pre-Clinical Efficacy of the Novel Kinase Inhibitor Nintedanib on PAX5 Fusion Genes in Pediatric Ph-like B-Cell Precursor Acute Lymphoblastic Leukemia

Grazia Fazio, Silvia Bresolin, Claudia Saitta, Daniela Silvestri, Elena Vendramini, Chiara Palmi, Silvia Rigamonti, Marta Galbiati, Manuel Quadri, Stefano Mecca, Angela Maria Savino, Michela Bardini, Andrea Grioni, Maria Grazia Valsecchi, PhD, Geertruy te Kronnie, Andrea Biondi, MD, Giovanni Cazzaniga, PhD

Blood (2019) 134 (Supplement_1): 745.

https://doi.org/10.1182/blood-2019-128509

Published: 2019

Journal Articles

Methodology for the Start-up of a Pediatric Hematopoietic Stem Cell Transplant Unit (pHSCTU) in Middle-Income Countries (MICs): An Exportable Model?

Marta Verna, MD, Attilio Rovelli, MD, Valentino Conter, MD, Marta Canesi, Nurse, Ignazio Majolino, MD, Dosti Othman, MD, Vian Faeq, MD, Jabibi Noguera, MD, Maria Liz Benitez, MD, Othman Dastan, MD, Andrea Biondi, MD PhD

Blood (2019) 134 (Supplement_1): 2044.

https://doi.org/10.1182/blood-2019-121922

Published: 2019

Journal Articles

Preclinical Assessment of Non-Virally Engineered CD33.CAR Cytokine-Induced Killer (CIK) Cells in Chemoresistant AML Patient-Derived Xenografts

Maria Caterina Rotiroti, PhD, Chiara Buracchi, PhD, Silvia Arcangeli, PhD, Chiara F Magnani, PhD, Claudia Cappuzzello, PhD, Zsuzsanna Izsvak, PhD, Stefania Galimberti, PhD, Maria Grazia Valsecchi, PhD, Giuseppe Dastoli, MD, Marta Serafini, PhD, Ettore Biagi, MD, Andrea Biondi, MD, Sarah Tettamanti, PhD

Blood (2019) 134 (Supplement_1): 2665.

https://doi.org/10.1182/blood-2019-130399

Published: 2019

Journal Articles

Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood (2019) 134 (Supplement_1): 200.

https://doi.org/10.1182/blood-2019-125894

Published: 2019

Journal Articles

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Carmelo Rizzari, Anja Moericke, MD, Valentino Conter, MD, Maria Grazia Valsecchi, PhD, Martin Zimmermann, PhD, Daniela Silvestri, Georg Mann, MD, Felix Niggli, MD, Luciano Dalla-Pozza, MBBS FRACP, Jan Stary, Prof., MD PhD, Sarah Elitzur, MD, Gunnar Cario, MD, Franco Locatelli, MD, Joachim Boos, MD, Massimo Zucchetti, PharmD, Andrea Biondi, MD, Martin Schrappe, MD PhD

Blood (2019) 134 (Supplement_1): 2589.

https://doi.org/10.1182/blood-2019-123448

Published: 2019

Journal Articles

Prognostic Value of Minimal Residual Disease Measured By Flow Cytometry in Two Cohorts of Infants with Acute Lymphoblastic Leukemia Treated with MLL-Baby and Interfant Protocols in Large Multicenter Networks

Blood (2019) 134 (Supplement_1): 2747.

https://doi.org/10.1182/blood-2019-130210

Published: 2019

Journal Articles

Poor Prognosis in Children with ABL -Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols

Blood (2019) 134 (Supplement_1): 1351.

https://doi.org/10.1182/blood-2019-126523

Published: 2019

Journal Articles

Flow Cytometric Measurement of the Initial In Vivo Response to Prednisone Provides New Prognostic Information in Childhood Acute Lymphoblastic Leukemia (ALL)

Giuseppe Gaipa, PhD, Oscar Maglia, Simona Sala, Bsc, Noemi Marino, Daniela Silvestri, Maria Grazia Valsecchi, PhD, Andrea Biondi, MD, Valentino Conter, MD

Blood (2018) 132 (Supplement 1): 2827.

https://doi.org/10.1182/blood-2018-99-116782

Published: 2018

Journal Articles

Digital-Droplet PCR, an Accurate Method for IG/TR PCR-MRD Stratification in Childhood Acute Lymphoblastic Leukemia

Irene Della Starza, PhD, Vittorio Nunes, Federica Lovisa, Daniela Silvestri, Marzia Cavalli, PhD, Andrea Garofalo, Mimma Campeggio, Lucia Anna De Novi, PhD, Carlotta Oggioni, Andrea Biondi, MD, Anna Guarini, PhD, Maria Grazia Valsecchi, PhD, Valentino Conter, MD, Giuseppe Basso, MD, Robin Foà, MD, Giovanni Cazzaniga, PhD

Blood (2018) 132 (Supplement 1): 1544.

https://doi.org/10.1182/blood-2018-99-117954

Published: 2018

Journal Articles

Specific Targeting of Acute Myeloid Leukemia By the Use of Non-Virally Engineered CIK (Cytokine-Induced Killer) Cells Expressing the Anti-CD33 Chimeric Antigen Receptor (CAR)

Maria Caterina Rotiroti, MSc, Silvia Arcangeli, PhD, Chiara Buracchi, PhD, Chiara Francesca Magnani, PhD, Claudia Cappuzzello, PhD, Ettore Biagi, MD, Sarah Tettamanti, PhD, Andrea Biondi, MD

Blood (2018) 132 (Supplement 1): 2201.

https://doi.org/10.1182/blood-2018-99-114572

Published: 2018

Journal Articles

Clinical-Grade Transduction of Allogeneic Cytokine Induced Killer (CIK) Cells with CD19 Chimeric Antigen Receptor (CAR) Using Sleeping Beauty (SB) Transposon: Successful GMP-Compliant Manufacturing for Clinical Applications

Blood (2018) 132 (Supplement 1): 196.

https://doi.org/10.1182/blood-2018-196

Published: 2018

Journal Articles

Outcome of Infants Younger Than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol; Results from an International Randomised Study

Blood (2018) 132 (Supplement 1): 655.

https://doi.org/10.1182/blood-2018-99-112854

Published: 2018

Journal Articles

Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Cirino Botta, MD, Giuseppe Gaipa, PhD, Maria Eugenia Gallo Cantafio, PhD, Chiara Buracchi, PhD, Maria Anna Siciliano, MD, Caterina Riillo, MD, Katia Grillone, PhD, Alessandro Gulino, Maria Cucè, Nicoletta Staropoli, Andrea Ghelli Luserna Di Rora, Franca Maria Tuccillo, Maria Teresa Di Martino, Claudio Tripodo, MD, Marco Rossi, MD, Giovanni Martinelli, Andrea Biondi, MD, Pierosandro Tagliaferri, Pierfrancesco Tassone, MD

Blood (2018) 132 (Supplement 1): 1418.

https://doi.org/10.1182/blood-2018-99-118572

Published: 2018

Journal Articles

Activin A, a Potential Key Factor of the Malignant Bone Marrow Niche, Enhances B-Cell Precursor-Acute Lymphoblastic Leukemic Cell Migratory and Invasive Properties

Erica Dander, PhD, Federica Portale, PhD, Daniela Silvestri, Giulia Cricrì, Silvia Bresolin, PhD, Stefania Gaspari, Barbara Russo, Monica Lupi, Paolo Ubezio, Geertruy te Kronnie, Maria Grazia Valsecchi, PhD, Franco Locatelli, Carmelo Rizzari, MD, Andrea Biondi, MD, Giovanna D'Amico, BSc, PhD MSc

Blood (2018) 132 (Supplement 1): 1296.

https://doi.org/10.1182/blood-2018-99-116668

Published: 2018

Journal Articles

Advanced Phases at Diagnosis of Childhood Chronic Myeloid Leukemia : The Experience of the International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped Study)

Frédéric Millot, Joelle Guilhot, PhD, Meinolf Suttorp, MD PhD, Natacha Maledon, Meral Günes Adalet, MD, Petr Sedlacek, MD, Eveline S. de Bont, MD, Chi Kong Li, MD, Krzysztof Kalwak, MD, Birgitte Lausen, MD, Gordana Jakovljevic, MD, Michael Dworzak, MD, Andrea Hraskova, MD, Barbara De Moerloose, MD PhD, Roula Farah, MD, Andrea Biondi, MD, Andre Baruchel, MD

Blood (2017) 130 (Supplement 1): 316.

https://doi.org/10.1182/blood.V130.Suppl_1.316.316

Published: 2017

NARROW

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Incidence and Therapeutic Implications of Germline TP53 Mutations in Hypodiploid Childhood Acute Lymphoblastic Leukemia: A Retrospective Analysis of the Italian Cohort

Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity

Single-Cell Profiling of Signal Transduction Pathways in Pediatric T-Cell Acute Lymphoblastic Leukemia By Mass Cytometry:Dissecting JAK/STAT and PI3K/Akt/mTOR Active Signalling

Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A -Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Pre-Clinical Efficacy of the Novel Kinase Inhibitor Nintedanib on PAX5 Fusion Genes in Pediatric Ph-like B-Cell Precursor Acute Lymphoblastic Leukemia

Methodology for the Start-up of a Pediatric Hematopoietic Stem Cell Transplant Unit (pHSCTU) in Middle-Income Countries (MICs): An Exportable Model?

Preclinical Assessment of Non-Virally Engineered CD33.CAR Cytokine-Induced Killer (CIK) Cells in Chemoresistant AML Patient-Derived Xenografts

Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Prognostic Value of Minimal Residual Disease Measured By Flow Cytometry in Two Cohorts of Infants with Acute Lymphoblastic Leukemia Treated with MLL-Baby and Interfant Protocols in Large Multicenter Networks

Poor Prognosis in Children with ABL -Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols

Flow Cytometric Measurement of the Initial In Vivo Response to Prednisone Provides New Prognostic Information in Childhood Acute Lymphoblastic Leukemia (ALL)

Digital-Droplet PCR, an Accurate Method for IG/TR PCR-MRD Stratification in Childhood Acute Lymphoblastic Leukemia

Specific Targeting of Acute Myeloid Leukemia By the Use of Non-Virally Engineered CIK (Cytokine-Induced Killer) Cells Expressing the Anti-CD33 Chimeric Antigen Receptor (CAR)

Clinical-Grade Transduction of Allogeneic Cytokine Induced Killer (CIK) Cells with CD19 Chimeric Antigen Receptor (CAR) Using Sleeping Beauty (SB) Transposon: Successful GMP-Compliant Manufacturing for Clinical Applications

Outcome of Infants Younger Than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol; Results from an International Randomised Study

Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Activin A, a Potential Key Factor of the Malignant Bone Marrow Niche, Enhances B-Cell Precursor-Acute Lymphoblastic Leukemic Cell Migratory and Invasive Properties

Advanced Phases at Diagnosis of Childhood Chronic Myeloid Leukemia : The Experience of the International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped Study)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only